Drug Trial Radar · NCT02469155
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
Last checked: Nov 20, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
696
Actual
Start
Jun 2015
Primary completion
Aug 2016
Study completion Aug 2016
Sponsor
- Lead sponsor
- Intra-Cellular Therapies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 11, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.
Conditions
- Schizophrenia
Interventions
ITI-007Drug
RisperidoneDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total ScoreTime frame: 6 weeks
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Clinical Site
Little Rock, Arkansas
Clinical Site
Springdale, Arkansas
Clinical Site
Culver City, California
Clinical Site
Lemon Grove, California
Clinical Site
Long Beach, California
Clinical Site
San Diego, California
Clinical Site
North Miami, Florida
Clinical Site
Berlin, New Jersey
Clinical Site
Marlton, New Jersey
Clinical Site
Austin, Texas
Clinical Site
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.